

Increased mortality in community-tested cases of SARS

Nature

593, 270-274

DOI: [10.1038/s41586-021-03426-1](https://doi.org/10.1038/s41586-021-03426-1)

Citation Report

#	ARTICLE	IF	CITATIONS
1	COVID-19 and the Kidney: Should Nephrologists Care about COVID-19 rather than Maintaining Their Focus on Renal Patients?. Contributions To Nephrology, 2021, 199, 1-15.	1.1	3
2	OUP accepted manuscript. American Journal of Clinical Pathology, 2021, , .	0.4	7
3	Epidemiological dynamics of SARS-CoV-2 VOC Gamma in Rio de Janeiro, Brazil. Virus Evolution, 2021, 7, veab087.	2.2	23
4	Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2 spike proteins associated with arising mutations in the D614G and Alpha variants. Glycobiology, 2022, 32, 60-72.	1.3	16
6	Genome Characterization of COVID-19 Lineage B.1.1.7 Detected in the First Six Patients of a Cluster Outbreak “ Shenzhen City, Guangdong Province, China, May 2021. China CDC Weekly, 2021, 3, 541-543.	1.0	3
8	SARS-CoV-2 spike protein N501Y mutation causes differential species transmissibility and antibody sensitivity: a molecular dynamics and alchemical free energy study. Molecular Systems Design and Engineering, 2021, 6, 964-974.	1.7	8
12	Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February. Eurosurveillance, 2021, 26, .	3.9	156
14	Why US coronavirus tracking can’t keep up with concerning variants. Nature, 2021, 592, 336-337.	13.7	23
16	SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation. ELife, 2021, 10, .	2.8	160
19	Rapid Spread of the SARS-CoV-2 Variant of Concern 202012/01 in Southern Italy (December 2020“March) Tj ETQq1 1 0.784314 rgBT 1.2 26	1.2	26
20	Obesity and its impact on COVID-19. Journal of Molecular Medicine, 2021, 99, 899-915.	1.7	41
21	Surveillance of SARS-CoV-2 in Frankfurt am Main from October to December 2020 Reveals High Viral Diversity Including Spike Mutation N501Y in B.1.1.70 and B.1.1.7. Microorganisms, 2021, 9, 748.	1.6	14
22	Evaluation of an Automated High-Throughput Liquid-Based RNA Extraction Platform on Pooled Nasopharyngeal or Saliva Specimens for SARS-CoV-2 RT-PCR. Viruses, 2021, 13, 615.	1.5	5
26	Genetic Diversity of SARS-CoV-2 over a One-Year Period of the COVID-19 Pandemic: A Global Perspective. Biomedicines, 2021, 9, 412.	1.4	22
27	Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Eurosurveillance, 2021, 26, .	3.9	216
28	Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science, 2021, 372, .	6.0	2,103
37	Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada. Vaccine, 2021, 39, 2360-2365.	1.7	30
39	Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies: Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations. Biochemistry, 2021, 60, 1459-1484.	1.2	62

#	ARTICLE	IF	CITATIONS
41	Implementing Personalized Medicine in COVID-19 in Andalusia: An Opportunity to Transform the Healthcare System. <i>Journal of Personalized Medicine</i> , 2021, 11, 475.	1.1	20
43	SARS-CoV-2 variants: A double-edged sword?. <i>Experimental Biology and Medicine</i> , 2021, 246, 1721-1726.	1.1	19
46	Trends Over Time in the Risk of Adverse Outcomes Among Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Clinical Infectious Diseases</i> , 2022, 74, 416-426.	2.9	20
47	Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection. <i>Journal of Infectious Diseases</i> , 2021, 224, 595-605.	1.9	20
52	Vaccinating children against SARS-CoV-2. <i>BMJ</i> , The, 2021, 373, n1197.	3.0	17
53	Emergence of the SARS-CoV-2 B.1.1.7 variant observed at the Poitiers University Hospital. <i>Journal of Medical Virology</i> , 2021, 93, 5254-5256.	2.5	0
56	Problems associated with antiviral drugs and vaccines development for COVID-19: approach to intervention using expression vectors via GPI anchor. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2021, 40, 665-706.	0.4	12
57	Repeated Exposure to Subinfectious Doses of SARS-CoV-2 May Promote T Cell Immunity and Protection against Severe COVID-19. <i>Viruses</i> , 2021, 13, 961.	1.5	11
58	COVID-19 rise in Bangladesh correlates with increasing detection of B.1.351 variant. <i>BMJ Global Health</i> , 2021, 6, e006012.	2.0	28
59	The Spike of Concern—The Novel Variants of SARS-CoV-2. <i>Viruses</i> , 2021, 13, 1002.	1.5	92
60	The Emerging Concern and Interest SARS-CoV-2 Variants. <i>Pathogens</i> , 2021, 10, 633.	1.2	86
62	Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in asymptomatic vaccinated healthcare workers. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 1-2.	1.0	3
63	Rapid vaccination and partial lockdown minimize 4th waves from emerging highly contagious SARS-CoV-2 variants. <i>Med</i> , 2021, 2, 573-574.	2.2	7
64	SARS-CoV-2 B.1.1.7 variant of concern detected in a pet dog and cat after exposure to a person with COVID-19, USA. <i>Transboundary and Emerging Diseases</i> , 2022, 69, 1656-1658.	1.3	53
65	SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies. <i>Nature Medicine</i> , 2021, 27, 759-761.	15.2	65
66	SARS-CoV-2 worldwide replication drives rapid rise and selection of mutations across the viral genome: a time-course study—potential challenge for vaccines and therapies. <i>EMBO Molecular Medicine</i> , 2021, 13, e14062.	3.3	28
69	Association Between Olfactory Dysfunction and Critical Illness and Mortality in COVID-19: A Meta-analysis. <i>Otolaryngology - Head and Neck Surgery</i> , 2022, 166, 388-392.	1.1	7
70	Clinical outcomes in COVID-19 patients infected with different SARS-CoV-2 variants in Marseille, France. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1516.e1-1516.e6.	2.8	18

#	ARTICLE	IF	CITATIONS
71	Monitoring differences between the SARS-CoV-2 B.1.1.7 variant and other lineages. <i>Lancet Public Health</i> , The, 2021, 6, e267-e268.	4.7	30
78	Immune response to SARS-CoV-2 variants of concern in vaccinated individuals. <i>Nature Communications</i> , 2021, 12, 3109.	5.8	118
80	Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals. <i>Viruses</i> , 2021, 13, 1135.	1.5	17
85	Sequence Analysis of 20,453 Severe Acute Respiratory Syndrome Coronavirus 2 Genomes from the Houston Metropolitan Area Identifies the Emergence and Widespread Distribution of Multiple Isolates of All Major Variants of Concern. <i>American Journal of Pathology</i> , 2021, 191, 983-992.	1.9	42
87	Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1507-1517.	4.6	129
89	Molecular epidemiology of SARS-CoV-2 isolated from COVID-19 family clusters. <i>BMC Medical Genomics</i> , 2021, 14, 144.	0.7	13
90	Exploiting a chink in the armor: engineering broadly neutralizing monoclonal antibodies for SARS-like viruses. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 232.	7.1	1
92	SARS-CoV-2 Infectivity and Severity of COVID-19 According to SARS-CoV-2 Variants: Current Evidence. <i>Journal of Clinical Medicine</i> , 2021, 10, 2635.	1.0	36
93	Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know?. <i>Journal of Clinical Medicine Research</i> , 2021, 13, 317-325.	0.6	134
100	Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1518-1528.	4.6	75
101	SARS-CoV-2 variants and considerations of inferring causality on disease severity. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1472-1474.	4.6	25
102	Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. <i>Science</i> , 2021, 373, .	6.0	318
103	Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants. <i>Science</i> , 2021, 373, 642-648.	6.0	211
106	SARS-CoV-2 variants of concern: the knowns and unknowns. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2021, 40, 100868.	0.6	5
107	Controlling the pandemic during the SARS-CoV-2 vaccination rollout. <i>Nature Communications</i> , 2021, 12, 3674.	5.8	98
108	Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	656
109	Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. <i>Nature Medicine</i> , 2021, 27, 1370-1378.	15.2	260
110	Replication Kinetics of B.1.351 and B.1.1.7 SARS-CoV-2 Variants of Concern Including Assessment of a B.1.1.7 Mutant Carrying a Defective ORF7a Gene. <i>Viruses</i> , 2021, 13, 1087.	1.5	34

#	ARTICLE	IF	CITATIONS
111	Translating All-Cause Mortality Rate Ratios or Hazard Ratios to Age-, Longevity-, and Probability-Based Measures. <i>American Journal of Epidemiology</i> , 2021, 190, 2664-2670.	1.6	3
113	Structure-function relations of the SARS-CoV-2 spike protein and impact of mutations in the variants of concern. <i>Comptes Rendus - Biologies</i> , 2021, 344, 77-110.	0.1	4
115	Coordinating SARS-CoV-2 genomic surveillance in the United States. <i>Virus Evolution</i> , 2021, 7, veab053.	2.2	3
116	Rapid Inactivation of SARS-CoV-2 Variants by Continuous and Intermittent Irradiation with a Deep-Ultraviolet Light-Emitting Diode (DUV-LED) Device. <i>Pathogens</i> , 2021, 10, 754.	1.2	17
117	Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. <i>Cell Reports</i> , 2021, 35, 109292.	2.9	375
118	Tackling COVID-19 with neutralizing monoclonal antibodies. <i>Cell</i> , 2021, 184, 3086-3108.	13.5	309
119	Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. <i>Nature Medicine</i> , 2021, 27, 1379-1384.	15.2	296
121	Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis. <i>BMJ, The</i> , 2021, 373, n1412.	3.0	114
123	Despite vaccination, China needs non-pharmaceutical interventions to prevent widespread outbreaks of COVID-19 in 2021. <i>Nature Human Behaviour</i> , 2021, 5, 1009-1020.	6.2	81
124	Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. <i>Cell</i> , 2021, 184, 3426-3437.e8.	13.5	424
125	Mortality risk in patients infected with SARS-CoV-2 of the lineage B.1.1.7 in the UK. <i>Journal of Infection</i> , 2021, 83, e14-e15.	1.7	13
126	Plitidepsin: Mechanisms and Clinical Profile of a Promising Antiviral Agent against COVID-19. <i>Journal of Personalized Medicine</i> , 2021, 11, 668.	1.1	16
127	SARS-CoV-2 viral dynamics in infections with Alpha and Beta variants of concern in the French community. <i>Journal of Infection</i> , 2021, , .	1.7	16
128	Detection of SARS-CoV-2 variant 501Y.V2 in Comoros Islands in January 2021. <i>Wellcome Open Research</i> , 2021, 6, 192.	0.9	7
130	High coverage COVID-19 mRNA vaccination rapidly controls SARS-CoV-2 transmission in long-term care facilities. <i>Communications Medicine</i> , 2021, 1, .	1.9	16
131	Unrecognized introduction of SARS-CoV-2 variants of concern to Central Africa: Import and local transmission of B.1.1.7 in Gabon in the very early stage of the variant spread to the African continent. <i>Journal of Medical Virology</i> , 2021, 93, 6054-6058.	2.5	3
132	Early detection of P.1 variant of SARS-CoV-2 in a cluster of cases in Salvador, Brazil. <i>International Journal of Infectious Diseases</i> , 2021, 108, 252-255.	1.5	17
133	An Update on Severe Acute Respiratory Syndrome Coronavirus 2 Diversity in the US National Capital Region: Evolution of Novel and Variants of Concern. <i>Clinical Infectious Diseases</i> , 2022, 74, 1419-1428.	2.9	24

#	ARTICLE	IF	CITATIONS
134	Variant Analysis of SARS-CoV-2 Genomes from Belgian Military Personnel Engaged in Overseas Missions and Operations. <i>Viruses</i> , 2021, 13, 1359.	1.5	6
135	Epidemiological and clinical presentations of hospitalized COVID-19 patients in Libya: An initial report from Africa. <i>Travel Medicine and Infectious Disease</i> , 2021, 42, 102064.	1.5	7
136	SARS-CoV-2 virulence evolution: Avirulence theory, immunity and trade-offs. <i>Journal of Evolutionary Biology</i> , 2021, 34, 1867-1877.	0.8	29
137	Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC) Tj ETQq1 1 0.784314 rgBT ₉₄ /Overlo	2.1	94
138	SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. <i>Cell Host and Microbe</i> , 2021, 29, 1124-1136.e11.	5.1	421
140	Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergence. <i>Science</i> , 2021, 373, 889-895.	6.0	142
141	Importance of mutations in amino acid 484 of the Spike protein of SARS-CoV-2: rapid detection by restriction enzyme analysis. <i>Investigacion Clinica</i> , 0, 62, 18-26.	0.0	2
142	Severe COVID-19 by SARS-CoV-2 Lineage B.1.1.7 in Vaccinated Solid-Organ Transplant Recipients: New Preventive Strategies Needed to Protect Immunocompromised Patients. <i>Vaccines</i> , 2021, 9, 806.	2.1	8
146	Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients. <i>Viruses</i> , 2021, 13, 1347.	1.5	12
148	Trends in ICU Mortality From Coronavirus Disease 2019: A Tale of Three Surges. <i>Critical Care Medicine</i> , 2022, 50, 245-255.	0.4	28
151	Hypothesis: Possible influence of antivector immunity and SARS-CoV-2 variants on efficacy of ChAdOx1 nCoV-19 vaccine. <i>British Journal of Pharmacology</i> , 2022, 179, 218-226.	2.7	11
152	Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination. <i>Clinical Infectious Diseases</i> , 2022, 74, 1623-1630.	2.9	42
155	Emergence of SARS-CoV-2 B.1.1.7 Lineage at Outpatient Testing Site, Berlin, Germany, January–March 2021. <i>Emerging Infectious Diseases</i> , 2021, 27, .	2.0	7
156	The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic. <i>Current Biology</i> , 2021, 31, R918-R929.	1.8	246
157	The molecular basis for SARS-CoV-2 binding to dog ACE2. <i>Nature Communications</i> , 2021, 12, 4195.	5.8	43
158	High-precision and cost-efficient sequencing for real-time COVID-19 surveillance. <i>Scientific Reports</i> , 2021, 11, 13669.	1.6	15
160	Mutation-Specific SARS-CoV-2 PCR Screen: Rapid and Accurate Detection of Variants of Concern and the Identification of a Newly Emerging Variant with Spike L452R Mutation. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0092621.	1.8	60
161	COVID-19 transmission and the safety of air travel during the pandemic: a scoping review. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 415-422.	1.3	13

#	ARTICLE	IF	CITATIONS
162	The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies. <i>Cell</i> , 2021, 184, 3949-3961.e11.	13.5	171
163	Broad sarbecovirus neutralization by a human monoclonal antibody. <i>Nature</i> , 2021, 597, 103-108.	13.7	220
164	Temporal Trends in ICU Survival for Coronavirus Disease 2019. <i>Critical Care Medicine</i> , 2021, Publish Ahead of Print, 1986-1988.	0.4	1
165	Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 288.	7.1	38
166	Prevalence, environmental fate, treatment strategies, and future challenges for wastewater contaminated with SARS-CoV-2. <i>Remediation</i> , 2021, 31, 97-110.	1.1	7
168	Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 4598.	5.8	88
169	Emergence and Spread of B.1.1.7 Lineage in Primary Care and Clinical Impact in the Morbi-Mortality among Hospitalized Patients in Madrid, Spain. <i>Microorganisms</i> , 2021, 9, 1517.	1.6	12
170	One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model. <i>Vaccine</i> , 2021, 39, 4885-4894.	1.7	15
171	A SARS-CoV-2 Nucleocapsid Variant that Affects Antigen Test Performance. <i>Journal of Clinical Virology</i> , 2021, 141, 104900.	1.6	53
173	The Alpha Variant (B.1.1.7) of SARS-CoV-2 in Children: First Experience from 3544 Nucleic Acid Amplification Tests in a Cohort of Children in Germany. <i>Viruses</i> , 2021, 13, 1600.	1.5	23
175	Validation of The 4C Deterioration Model for COVID-19 in a UK Teaching Hospital During Wave 2. <i>American Journal of the Medical Sciences</i> , 2021, 362, 512-515.	0.4	3
176	SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment. <i>Annual Review of Medicine</i> , 2022, 73, 1-16.	5.0	91
177	Stopping the COVID-19 pandemic in dental offices: A review of SARS-CoV-2 transmission and cross-infection prevention. <i>Experimental Biology and Medicine</i> , 2021, 246, 2381-2390.	1.1	6
178	An Outbreak of COVID-19 among mRNA-Vaccinated Nursing Home Residents. <i>Vaccines</i> , 2021, 9, 859.	2.1	13
181	A cross-sectional overview of SARS-CoV-2 genome variations in Turkey. <i>Turkish Journal of Biochemistry</i> , 2021, .	0.3	1
182	One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages. <i>Infection, Genetics and Evolution</i> , 2021, 92, 104869.	1.0	49
183	Facing the wrath of enigmatic mutations: a review on the emergence of severe acute respiratory syndrome coronavirus 2 variants amid coronavirus disease-19 pandemic. <i>Environmental Microbiology</i> , 2022, 24, 2615-2629.	1.8	23
184	SARS-CoV-2 testing and sequencing for international arrivals reveals significant cross border transmission of high risk variants into the United Kingdom. <i>EClinicalMedicine</i> , 2021, 38, 101021.	3.2	24

#	ARTICLE	IF	CITATIONS
185	Replicative Fitness of a SARS-CoV-2 20I/501Y.V1 Variant from Lineage B.1.1.7 in Human Reconstituted Bronchial Epithelium. <i>MBio</i> , 2021, 12, e0085021.	1.8	27
186	Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta). <i>Clinical Infectious Diseases</i> , 2022, 75, e1128-e1136.	2.9	323
187	Jumping a Moving Train: SARS-CoV-2 Evolution in Real Time. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, S96-S105.	0.6	9
188	Circulating SARS-CoV-2 variants in Italy, October 2020â€“March 2021. <i>Virology Journal</i> , 2021, 18, 168.	1.4	36
189	SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants. <i>Viruses</i> , 2021, 13, 1687.	1.5	57
190	A modelling study investigating short and medium-term challenges for COVID-19 vaccination: From prioritisation to the relaxation of measures. <i>EClinicalMedicine</i> , 2021, 38, 101001.	3.2	45
191	High throughput diagnostics and dynamic risk assessment of SARS-CoV-2 variants of concern. <i>EBioMedicine</i> , 2021, 70, 103540.	2.7	15
192	Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant. <i>Biochemical and Biophysical Research Communications</i> , 2021, 566, 135-140.	1.0	46
193	SARS-CoV-2 R.1 lineage variants that prevailed in Tokyo in March 2021. <i>Journal of Medical Virology</i> , 2021, 93, 6833-6836.	2.5	12
194	Global survey-based assessment of lifestyle changes during the COVID-19 pandemic. <i>PLoS ONE</i> , 2021, 16, e0255399.	1.1	3
195	Patients Admitted for Variant Alpha COVID-19 Have Poorer Outcomes than Those Infected with the Old Strain. <i>Journal of Clinical Medicine</i> , 2021, 10, 3550.	1.0	11
197	Phosphorylation of SARS-CoV-2 Orf9b Regulates Its Targeting to Two Binding Sites in TOM70 and Recruitment of Hsp90. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9233.	1.8	15
198	SARS-CoV-2 Tests: Bridging the Gap between Laboratory Sensors and Clinical Applications. <i>ACS Sensors</i> , 2021, 6, 2815-2837.	4.0	24
199	Design and rationale of the colchicine/statin for the prevention of COVID-19 complications (COLSTAT) trial. <i>Contemporary Clinical Trials</i> , 2021, 110, 106547.	0.8	4
200	Systematic review of host genetic association with Covidâ€“19 prognosis and susceptibility: What have we learned in 2020?. <i>Reviews in Medical Virology</i> , 2022, 32, e2283.	3.9	15
201	Alpha variant (B.1.1.7) of SARS-CoV-2 increases fatality-rate for patients under age of 70 years and hospitalization risk overall. <i>Acta Microbiologica Et Immunologica Hungarica</i> , 2021, , .	0.4	10
202	Cross-Neutralizing Activity Against SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in Japan. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab430.	0.4	18
203	The macroeconomics of COVID-19 exit strategy: the case of Japan. <i>Japanese Economic Review</i> , 2021, 72, 651-682.	0.8	15

#	ARTICLE	IF	CITATIONS
204	Emergence of SARS-CoV-2 Alpha (B.1.1.7) variant, infection rates, antibody seroconversion and seroprevalence rates in secondary school students and staff: Active prospective surveillance, December 2020 to March 2021, England. <i>Journal of Infection</i> , 2021, 83, 573-580.	1.7	18
205	A nationwide analysis of population group differences in the COVID-19 epidemic in Israel, February 2020 to February 2021. <i>Lancet Regional Health - Europe</i> , 2021, 7, 100130.	3.0	49
206	Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies. <i>PLoS Pathogens</i> , 2021, 17, e1009772.	2.1	74
208	Monitoring Emergence of the SARS-CoV-2 B.1.1.7 Variant through the Spanish National SARS-CoV-2 Wastewater Surveillance System (VATar COVID-19). <i>Environmental Science & Technology</i> , 2021, 55, 11756-11766.	4.6	39
209	Whole Genome Sequencing of SARS-CoV-2 Strains in COVID-19 Patients From Djibouti Shows Novel Mutations and Clades Replacing Over Time. <i>Frontiers in Medicine</i> , 2021, 8, 737602.	1.2	4
210	Multiorgan tropism of SARS-CoV-2 lineage B.1.1.7. <i>International Journal of Legal Medicine</i> , 2021, 135, 2347-2349.	1.2	12
211	Effective Preventive Strategies to Prevent Secondary Transmission of COVID-19 in Hemodialysis Unit: The First Month of Community Outbreak in Taiwan. <i>Healthcare (Switzerland)</i> , 2021, 9, 1173.	1.0	5
212	Superspreading in the emergence of COVID-19 variants. <i>Trends in Genetics</i> , 2021, 37, 1069-1080.	2.9	31
214	Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies. <i>Biomedicines</i> , 2021, 9, 1163.	1.4	18
215	Of bats and men: Immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection. <i>Science Immunology</i> , 2021, 6, eabd0205.	5.6	26
216	Fast SARS-CoV-2 Variant Detection Using Snapback Primer High-Resolution Melting. <i>Diagnostics</i> , 2021, 11, 1788.	1.3	8
217	Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study. <i>The Lancet Global Health</i> , 2021, 9, e1216-e1225.	2.9	131
218	Interleukin-1RA Mitigates SARS-CoV-2-Induced Inflammatory Lung Vascular Leakage and Mortality in Humanized K18-hACE-2 Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2773-2785.	1.1	20
219	Severity of Severe Acute Respiratory System Coronavirus 2 (SARS-CoV-2) Alpha Variant (B.1.1.7) in England. <i>Clinical Infectious Diseases</i> , 2022, 75, e1120-e1127.	2.9	71
220	The SARS-CoV-2 B.1.1.7 variant and increased clinical severity—the jury is out. <i>Lancet Infectious Diseases</i> , 2021, 21, 1213-1214.	4.6	25
221	Comparative study of SmartAmp assay and reverse transcription-polymerase chain reaction by saliva specimen for the diagnosing COVID-19. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 120-123.	0.8	4
222	Genome interaction of the virus and the host genes and non-coding RNAs in SARS-CoV-2 infection. <i>Immunobiology</i> , 2021, 226, 152130.	0.8	10
223	Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication. <i>Nature Metabolism</i> , 2021, 3, 1466-1475.	5.1	76

#	ARTICLE	IF	CITATIONS
225	Low dose inocula of SARS-CoV-2 Alpha variant transmits more efficiently than earlier variants in hamsters. <i>Communications Biology</i> , 2021, 4, 1102.	2.0	20
227	SARS-CoV-2 N gene dropout and N gene Ct value shift as indicator for the presence of B.1.1.7 lineage in a commercial multiplex PCR assay. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1353.e1-1353.e5.	2.8	39
228	Myocardial Damage by SARS-CoV-2: Emerging Mechanisms and Therapies. <i>Viruses</i> , 2021, 13, 1880.	1.5	11
229	Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission. <i>Viruses</i> , 2021, 13, 1921.	1.5	10
230	COVID-19 Critical Illness: A Data-Driven Review. <i>Annual Review of Medicine</i> , 2022, 73, 95-111.	5.0	20
231	Atomistic Simulations and In Silico Mutational Profiling of Protein Stability and Binding in the SARS-CoV-2 Spike Protein Complexes with Nanobodies: Molecular Determinants of Mutational Escape Mechanisms. <i>ACS Omega</i> , 2021, 6, 26354-26371.	1.6	11
232	Exploring the Interaction between E484K and N501Y Substitutions of SARS-CoV-2 in Shaping the Transmission Advantage of COVID-19 in Brazil: A Modeling Study. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 1247-1254.	0.6	5
233	Genomic sequencing of SARS-CoV-2 in Rwanda reveals the importance of incoming travelers on lineage diversity. <i>Nature Communications</i> , 2021, 12, 5705.	5.8	24
235	Lack of detail in population-level data impedes analysis of SARS-CoV-2 variants of concern and clinical outcomes. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1195-1197.	4.6	29
236	Profiling CD8+ T cell epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants. <i>Cell Reports</i> , 2021, 36, 109708.	2.9	42
237	The Proportion of SARS-CoV-2 Infections That Are Asymptomatic. <i>Annals of Internal Medicine</i> , 2021, 174, 1343-1344.	2.0	2
238	Clinical Course and Outcome of Patients with SARS-CoV-2 Alpha Variant Infection Compared to Patients with SARS-CoV-2 Wild-Type Infection Admitted to the ICU. <i>Microorganisms</i> , 2021, 9, 1944.	1.6	8
239	Clinical characteristics of COVID-19 in Osaka, Japan: Comparison of the first and third waves with the fourth wave. <i>Respiratory Investigation</i> , 2021, 59, 810-818.	0.9	16
240	The biological and clinical significance of emerging SARS-CoV-2 variants. <i>Nature Reviews Genetics</i> , 2021, 22, 757-773.	7.7	778
241	Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis. <i>Biomedicines</i> , 2021, 9, 1303.	1.4	87
242	In silico study on the effect of SARS-CoV-2 RBD hotspot mutants' interaction with ACE2 to understand the binding affinity and stability. <i>Virology</i> , 2021, 561, 107-116.	1.1	44
243	Genomic and Epidemiological Analysis of SARS-CoV-2 Viruses in Sri Lanka. <i>Frontiers in Microbiology</i> , 2021, 12, 722838.	1.5	9
244	Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range of characteristics. <i>Nature Communications</i> , 2021, 12, 5730.	5.8	90

#	ARTICLE	IF	CITATIONS
245	SARS-CoV-2 lineage B.1.1.7 is associated with greater disease severity among hospitalised women but not men: multicentre cohort study. <i>BMJ Open Respiratory Research</i> , 2021, 8, e001029.	1.2	22
246	Social distancing and preventive practices of government employees in response to COVID-19 in Ethiopia. <i>PLoS ONE</i> , 2021, 16, e0257112.	1.1	12
247	SARS-CoV-2 Quasispecies Provides an Advantage Mutation Pool for the Epidemic Variants. <i>Microbiology Spectrum</i> , 2021, 9, e0026121.	1.2	47
248	Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK. <i>Lancet Microbe</i> , The, 2021, 2, e416-e418.	3.4	16
249	The real-life impact of vaccination on COVID-19 mortality in Europe and Israel. <i>Public Health</i> , 2021, 198, 230-237.	1.4	70
250	A look into the future of the COVID-19 pandemic in Europe: an expert consultation. <i>Lancet Regional Health - Europe</i> , The, 2021, 8, 100185.	3.0	72
251	Wave-wise comparative genomic study for revealing the complete scenario and dynamic nature of COVID-19 pandemic in Bangladesh. <i>PLoS ONE</i> , 2021, 16, e0258019.	1.1	13
252	Precision Response to the Rise of the SARS-CoV-2 B.1.1.7 Variant of Concern by Combining Novel PCR Assays and Genome Sequencing for Rapid Variant Detection and Surveillance. <i>Microbiology Spectrum</i> , 2021, 9, e0031521.	1.2	35
253	Changing composition of SARS-CoV-2 lineages and rise of Delta variant in England. <i>EClinicalMedicine</i> , 2021, 39, 101064.	3.2	116
254	Different Strategies for the Identification of SARS-CoV-2 Variants in the Laboratory Practice. <i>Genes</i> , 2021, 12, 1428.	1.0	8
255	Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro. <i>Pharmaceutics</i> , 2021, 13, 1400.	2.0	35
257	Detection of SARS-CoV-2 spike protein D614G mutation by qPCR-HRM analysis. <i>Heliyon</i> , 2021, 7, e07936.	1.4	10
258	Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	44
259	Vitamin D and COVID-19: An Overview of Recent Evidence. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10559.	1.8	36
260	Altered demographic profile of hospitalizations during the second COVID-19 wave in Amazonas, Brazil. <i>The Lancet Regional Health Americas</i> , 2021, 2, 100064.	1.5	0
261	COVID-19, the first pandemic in the post-genomic era. <i>Current Opinion in Virology</i> , 2021, 50, 40-48.	2.6	40
262	Technical framework for wastewater-based epidemiology of SARS-CoV-2. <i>Science of the Total Environment</i> , 2021, 791, 148271.	3.9	18
263	Investigating the possible origin and transmission routes of SARS-CoV-2 genomes and variants of concern in Bangladesh. <i>Infection, Genetics and Evolution</i> , 2021, 95, 105057.	1.0	2

#	ARTICLE	IF	CITATIONS
264	Clinical outcomes in patients infected with different SARS-CoV-2 variants at one hospital during three phases of the COVID-19 epidemic in Marseille, France. <i>Infection, Genetics and Evolution</i> , 2021, 95, 105092.	1.0	22
265	Antibody persistence and neutralising activity in primary school students and staff: Prospective active surveillance, June to December 2020, England. <i>EClinicalMedicine</i> , 2021, 41, 101150.	3.2	8
266	Collapse of the public health system and the emergence of new variants during the second wave of the COVID-19 pandemic in Brazil. <i>One Health</i> , 2021, 13, 100287.	1.5	78
267	Phylogeneticity of B.1.1.7 surface glycoprotein, novel distance function and first report of V90T missense mutation in SARS-CoV-2 surface glycoprotein. <i>Meta Gene</i> , 2021, 30, 100967.	0.3	4
268	SARS-CoV-2 wastewater surveillance data can predict hospitalizations and ICU admissions. <i>Science of the Total Environment</i> , 2022, 804, 150151.	3.9	116
269	A New SARS-CoV-2 Variant Poorly Detected by RT-PCR on Nasopharyngeal Samples, with High Lethality. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
271	Identification of fragments binding to SARS-CoV-2 nsp10 reveals ligand-binding sites in conserved interfaces between nsp10 and nsp14/nsp16. <i>RSC Chemical Biology</i> , 2022, 3, 44-55.	2.0	23
272	Variantes Alpha y Gamma del SARS-CoV-2: revisión rápida para contribuir en la toma de decisiones. <i>Revista De La Universidad Industrial De Santander Salud</i> , 2021, 53, .	0.0	0
273	Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 757197.	2.2	20
274	INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2021, 6, 121.	2.9	36
275	Cellular senescence as a source of SARS-CoV-2 quasispecies. <i>FEBS Journal</i> , 2023, 290, 1384-1392.	2.2	12
276	Analysis of Severe Acute Respiratory Syndrome 2 Replication in Explant Cultures of the Human Upper Respiratory Tract Reveals Broad Tissue Tropism of Wild-Type and B.1.1.7 Variant Viruses. <i>Journal of Infectious Diseases</i> , 2021, 224, 2020-2024.	1.9	5
277	Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore. <i>Npj Vaccines</i> , 2021, 6, 125.	2.9	17
278	Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 202-221.	2.8	569
279	Molecular Analysis and Genome Sequencing of SARS-Cov-2 during Second Wave 2021 Revealed Variant Diversity in India. <i>Journal of Pure and Applied Microbiology</i> , 0, , .	0.3	1
280	mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status. <i>ELife</i> , 2021, 10, .	2.8	63
281	Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques. <i>Science Advances</i> , 2021, 7, eabj3627.	4.7	24
283	Assessing Multiplex Tiling PCR Sequencing Approaches for Detecting Genomic Variants of SARS-CoV-2 in Municipal Wastewater. <i>MSystems</i> , 2021, 6, e0106821.	1.7	26

#	ARTICLE	IF	CITATIONS
284	Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants. <i>Expert Review of Vaccines</i> , 2022, 21, 47-67.	2.0	3
285	A new SARS-CoV-2 variant with high lethality poorly detected by RT-PCR on nasopharyngeal samples: an observational study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 298.e9-298.e15.	2.8	13
286	The global epidemic of SARS-CoV-2 variants and their mutational immune escape. <i>Journal of Medical Virology</i> , 2022, 94, 847-857.	2.5	80
288	Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments. <i>Current Molecular Medicine</i> , 2022, 22, 621-639.	0.6	2
289	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Dose, Infection, and Disease Outcomes for Coronavirus Disease 2019 (COVID-19): A Review. <i>Clinical Infectious Diseases</i> , 2022, 75, e1195-e1201.	2.9	13
290	Virologic Features of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children. <i>Journal of Infectious Diseases</i> , 2021, 224, 1821-1829.	1.9	53
291	Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort. <i>Science Translational Medicine</i> , 2022, 14, eabj7521.	5.8	71
292	Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. <i>Vaccines</i> , 2021, 9, 1195.	2.1	90
293	Endonuclease-based genotyping of the RBM as a method to track the emergence or evolution of SARS-CoV-2 variants. <i>IScience</i> , 2021, 24, 103329.	1.9	0
294	Increased risk of hospitalisation and intensive care admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway, December 2020 – May 2021. <i>PLoS ONE</i> , 2021, 16, e0258513.	1.1	37
298	Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines. <i>Viruses</i> , 2021, 13, 2127.	1.5	6
299	Conceptual causal framework to assess the effect of SARS-CoV-2 variants on COVID-19 disease severity among hospitalized patients. <i>Archives of Public Health</i> , 2021, 79, 185.	1.0	10
300	Increased risk of death in COVID-19 hospital admissions during the second wave as compared to the first epidemic wave: a prospective, single-centre cohort study in London, UK. <i>Infection</i> , 2022, 50, 457-465.	2.3	11
302	SARS-CoV-2 Variants Detection Using TaqMan SARS-CoV-2 Mutation Panel Molecular Genotyping Assays. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 4471-4479.	1.1	30
303	Rapid and High-Throughput Reverse Transcriptase Quantitative PCR (RT-qPCR) Assay for Identification and Differentiation between SARS-CoV-2 Variants B.1.1.7 and B.1.351. <i>Microbiology Spectrum</i> , 2021, 9, e0050621.	1.2	19
304	Acute SARS-CoV-2 alpha variant infection leading to placental insufficiency and fetal distress. <i>Journal of Medical Virology</i> , 2022, 94, 1196-1200.	2.5	12
305	mRNA-Based Vaccine BNT162b2 Might Reduce Severe Acute Respiratory Syndrome Coronavirus 2 B.1.1.7 Variant Transmission in Japanese Population. <i>Cureus</i> , 2021, 13, e19140.	0.2	0
306	BNT162b2 vaccine effectiveness was marginally affected by the SARS-CoV-2 beta variant in fully vaccinated individuals. <i>Journal of Clinical Epidemiology</i> , 2022, 142, 38-44.	2.4	12

#	ARTICLE	IF	CITATIONS
307	Lives saved and hospitalizations averted by COVID-19 vaccination in New York City: a modeling study. <i>The Lancet Regional Health Americas</i> , 2022, 5, 100085.	1.5	30
308	Cognitive Barriers to COVID-19 Vaccine Uptake Among Older Adults. <i>Frontiers in Medicine</i> , 2021, 8, 756275.	1.2	11
309	Possible harm from glucocorticoid drugs misuse in the early phase of SARS-CoV-2 infection: a narrative review of the evidence. <i>Internal and Emergency Medicine</i> , 2022, 17, 329-338.	1.0	13
310	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> , 2021, 8, e934-e946.	2.2	46
311	Functional differences among the spike glycoproteins of multiple emerging severe acute respiratory syndrome coronavirus 2 variants of concern. <i>IScience</i> , 2021, 24, 103393.	1.9	17
312	Survey of SARS-CoV-2 genetic diversity in two major Brazilian cities using a fast and affordable Sanger sequencing strategy. <i>Genomics</i> , 2021, 113, 4109-4115.	1.3	9
313	UK B.1.1.7 (Alpha) variant exhibits increased respiratory replication and shedding in nonhuman primates. <i>Emerging Microbes and Infections</i> , 2021, 10, 2173-2182.	3.0	19
314	Decisive conditions for strategic vaccination against SARS-CoV-2. <i>Chaos</i> , 2021, 31, 101105.	1.0	4
315	SARS-CoV-2 Mutations and Variants: what do we know so far?. <i>Microbes, Infection and Chemotherapy</i> , 0, 1, e1256.	0.0	5
317	The Evolutionary Landscape of SARS-CoV-2 Variant B.1.1.519 and Its Clinical Impact in Mexico City. <i>Viruses</i> , 2021, 13, 2182.	1.5	31
318	A review of epidemiology, clinical features and disease course, transmission dynamics, and neutralization efficacy of SARS-CoV-2 variants. <i>Egyptian Journal of Bronchology</i> , 2021, 15, .	0.3	4
319	SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence. <i>Epidemiology and Infection</i> , 2021, 149, 1-24.	1.0	43
320	Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational retrospective study. <i>EBioMedicine</i> , 2021, 73, 103637.	2.7	19
321	The way of SARS-CoV-2 vaccine development: success and challenges. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 387.	7.1	42
322	A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. <i>Science Translational Medicine</i> , 2022, 14, eabj7125.	5.8	93
324	Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape. <i>Frontiers in Immunology</i> , 2021, 12, 744242.	2.2	44
325	Optimal biologics for juvenile idiopathic arthritis in an infection with SARS-CoV-2 variant. <i>Pediatric Allergy and Immunology</i> , 2022, 33, .	1.1	1
327	A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection. <i>Npj Vaccines</i> , 2021, 6, 143.	2.9	47

#	ARTICLE	IF	CITATIONS
329	Parenchymal involvement on CT pulmonary angiography in SARS-CoV-2 Alpha variant infection and correlation of COVID-19 CT severity score with clinical disease severity and short-term prognosis in a UK cohort. <i>Clinical Radiology</i> , 2022, 77, 148-155.	0.5	6
330	The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice. <i>ELife</i> , 2021, 10, .	2.8	24
331	Trends in clinical severity of hospitalized patients with COVID-19, Premier Hospital Dataset, April 2020 – April 2021. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab599.	0.4	3
332	Alpha (B.1.1.7) and Delta (B.1.617.2 – AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage. <i>Journal of Infection</i> , 2022, 84, 418-467.	1.7	4
334	The Role of Serology Testing in the Context of Immunization Policies for COVID-19 in Latin American Countries. <i>Viruses</i> , 2021, 13, 2391.	1.5	11
335	Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 612.e1-612.e7.	2.8	231
337	Changing Features of COVID-19: Characteristics of Infections with the SARS-CoV-2 Delta (B.1.617.2) and Alpha (B.1.1.7) Variants in Southern Italy. <i>Vaccines</i> , 2021, 9, 1354.	2.1	15
338	The SARS-CoV-2 Pandemic in High Income Countries Such as Canada: A Better Way Forward Without Lockdowns. <i>Frontiers in Public Health</i> , 2021, 9, 715904.	1.3	7
339	The Disease Severity and Clinical Outcomes of the SARS-CoV-2 Variants of Concern. <i>Frontiers in Public Health</i> , 2021, 9, 775224.	1.3	156
340	Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 771242.	2.2	15
341	Tracking and Controlling the Spatiotemporal Spread of SARS-CoV-2 Lineage B.1.1.7 in COVID-19 Reopenings. <i>GeoHealth</i> , 2021, 5, e2021GH000517.	1.9	7
342	Antibody cocktail effective against variants of SARS-CoV-2. <i>Journal of Biomedical Science</i> , 2021, 28, 80.	2.6	17
343	Phylogenomics and population genomics of SARS-CoV-2 in Mexico during the pre-vaccination stage reveals variants of interest B.1.1.28.4 and B.1.1.222 or B.1.1.519 and the nucleocapsid mutation S194L associated with symptoms. <i>Microbial Genomics</i> , 2021, 7, .	1.0	13
344	Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2. <i>Cell Host and Microbe</i> , 2021, 29, 1788-1801.e6.	5.1	145
346	Common Laboratory Mice Are Susceptible to Infection with the SARS-CoV-2 Beta Variant. <i>Viruses</i> , 2021, 13, 2263.	1.5	21
347	Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill – An interim analysis of a nationwide cohort study. <i>PLoS ONE</i> , 2021, 16, e0258704.	1.1	12
348	Optimization and Clinical Validation of Colorimetric Reverse Transcription Loop-Mediated Isothermal Amplification, a Fast, Highly Sensitive and Specific COVID-19 Molecular Diagnostic Tool That Is Robust to Detect SARS-CoV-2 Variants of Concern. <i>Frontiers in Microbiology</i> , 2021, 12, 713713.	1.5	22
349	Re-emergence of Gamma-like-II and emergence of Gamma-S:E661D SARS-CoV-2 lineages in the south of Brazil after the 2021 outbreak. <i>Virology Journal</i> , 2021, 18, 222.	1.4	8

#	ARTICLE	IF	CITATIONS
350	Incidence Trends for SARS-CoV-2 Alpha and Beta Variants, Finland, Spring 2021. <i>Emerging Infectious Diseases</i> , 2021, 27, 3137-3141.	2.0	13
351	A quantitative assessment of epidemiological parameters required to investigate COVID-19 burden. <i>Epidemics</i> , 2021, 37, 100530.	1.5	8
352	Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England. <i>The Lancet Healthy Longevity</i> , 2021, 2, e811-e819.	2.0	54
353	SARS-CoV-2 Antibody Neutralization Assay Platforms Based on Epitopes Sources: Live Virus, Pseudovirus, and Recombinant S Glycoprotein RBD. <i>Immune Network</i> , 2021, 21, e39.	1.6	3
354	Microsimulation based quantitative analysis of COVID-19 management strategies. <i>PLoS Computational Biology</i> , 2022, 18, e1009693.	1.5	19
355	Genome sequencing of SARS-CoV-2 reveals the prevalence of variant B.1.1.7 in Egypt. <i>Infection, Genetics and Evolution</i> , 2022, 97, 105191.	1.0	3
356	Outcome of SARS-CoV-2 variant breakthrough infection in fully immunized solid organ transplant recipients. <i>Journal of Infection and Public Health</i> , 2022, 15, 51-55.	1.9	7
358	Rapid and accurate detection of SARS-CoV-2 mutations using a Cas12a-based sensing platform. <i>Biosensors and Bioelectronics</i> , 2022, 198, 113857.	5.3	31
359	A comprehensive overview of identified mutations in SARS CoV-2 spike glycoprotein among Iranian patients. <i>Gene</i> , 2022, 813, 146113.	1.0	8
360	Impact of vaccination and non-pharmaceutical interventions on SARS-CoV-2 dynamics in Switzerland. <i>Epidemics</i> , 2022, 38, 100535.	1.5	29
361	Epidemiokinetic Tools to Monitor Lockdown Efficacy and Estimate the Duration Adequate to Control SARS-CoV-2 Spread. <i>Journal of Epidemiology and Global Health</i> , 2021, 11, 321-325.	1.1	5
362	SARS-CoV-2 variant detection from wastewater: rapid spread of B.1.1.7 lineage in Hungary. <i>Journal of Water and Health</i> , 2022, 20, 277-286.	1.1	6
363	Monitoring of SARS-CoV-2 Variants by Wastewater-Based Surveillance as a Sustainable and Pragmatic Approach—A Case Study of Jaipur (India). <i>Water (Switzerland)</i> , 2022, 14, 297.	1.2	11
364	Epidemiological characteristics of the B.1.526 SARS-CoV-2 variant. <i>Science Advances</i> , 2022, 8, eabm0300.	4.7	6
366	Conformational Flexibility and Local Frustration in the Functional States of the SARS-CoV-2 Spike B.1.1.7 and B.1.351 Variants: Mutation-Induced Allosteric Modulation Mechanism of Functional Dynamics and Protein Stability. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1646.	1.8	2
367	Assessing the risk of vaccine-driven virulence evolution in SARS-CoV-2. <i>Royal Society Open Science</i> , 2022, 9, 211021.	1.1	8
368	Impact of regional heterogeneity on the severity of COVID-19. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 554-557.	0.8	2
369	Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study. <i>Lancet Rheumatology</i> , The, 2022, 4, e274-e281.	2.2	19

#	ARTICLE	IF	CITATIONS
370	Resolution of viral load in mild COVID-19 patients is associated with both innate and adaptive immune responses. <i>Journal of Clinical Virology</i> , 2022, 146, 105060.	1.6	14
371	The ins and outs of SARS-CoV-2 variants of concern (VOCs). <i>Archives of Virology</i> , 2022, 167, 327-344.	0.9	35
372	First and second waves among hospitalised patients with COVID-19 with severe pneumonia: a comparison of 28-day mortality over the 1-year pandemic in a tertiary university hospital in Italy. <i>BMJ Open</i> , 2022, 12, e054069.	0.8	13
373	Is the Alpha Variant of SARS-CoV-2 Associated with a Higher Viral Load than the Historical Strain in Saliva Samples in Patients with Mild to Moderate Symptoms?. <i>Life</i> , 2022, 12, 163.	1.1	2
375	Early-stage spatial disease surveillance of novel SARS-CoV-2 variants of concern in Germany with crowdsourced data. <i>Scientific Reports</i> , 2022, 12, 899.	1.6	8
376	Spread of variants of epidemic disease based on the microscopic numerical simulations on networks. <i>Scientific Reports</i> , 2022, 12, 523.	1.6	6
377	Effectiveness and Efficacy of Vaccine on Mutated SARS-CoV-2 Virus and Post Vaccination Surveillance: A Narrative Review. <i>Vaccines</i> , 2022, 10, 82.	2.1	16
378	Emergence of SARS-CoV-2 Variants in the World: How Could This Happen?. <i>Life</i> , 2022, 12, 194.	1.1	25
379	Background risk should be taken into account when reporting vaccine effectiveness. <i>American Journal of Transplantation</i> , 2022, , .	2.6	1
380	Setting-Up a Rapid SARS-CoV-2 Genome Assessment by Next-Generation Sequencing in an Academic Hospital Center (LPCE, Louis Pasteur Hospital, Nice, France). <i>Frontiers in Medicine</i> , 2021, 8, 730577.	1.2	5
381	Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug Development. <i>Molecules</i> , 2022, 27, 536.	1.7	39
382	Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants. <i>Frontiers in Medicine</i> , 2021, 8, 836826.	1.2	15
383	SARS-COV-2 Variants: Differences and Potential of Immune Evasion. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 781429.	1.8	154
385	Colloidal Virus Particles with Hierarchical Nanomorphology and Facile Biosurface Modification. <i>Chinese Journal of Chemistry</i> , 0, , .	2.6	0
386	Inequitable COVID-19 vaccine distribution and the intellectual property rights prolong the pandemic. <i>Expert Review of Vaccines</i> , 2022, 21, 427-430.	2.0	30
387	Estimating the transmissibility of SARS-CoV-2 VOC 202012/01 in Japan using travel history information. <i>Mathematical Biosciences and Engineering</i> , 2022, 19, 2750-2761.	1.0	0
388	Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. <i>Journal of Biomedical Science</i> , 2022, 29, 1.	2.6	144
389	Pandemic strategies with computational and structural biology against COVID-19: A retrospective. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 187-192.	1.9	6

#	ARTICLE	IF	CITATIONS
390	COVID-19 reinfections among naturally infected and vaccinated individuals. <i>Scientific Reports</i> , 2022, 12, 1438.	1.6	79
391	Differential COVID-19 Symptoms Given Pandemic Locations, Time, and Comorbidities During the Early Pandemic. <i>Frontiers in Medicine</i> , 2022, 9, 770031.	1.2	10
392	Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222. <i>Clinical and Experimental Immunology</i> , 2022, 208, 323-331.	1.1	3
393	Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron Variant. <i>New England Journal of Medicine</i> , 2022, 386, e14.	13.9	124
394	SARS-CoV-2 genomes from Saudi Arabia implicate nucleocapsid mutations in host response and increased viral load. <i>Nature Communications</i> , 2022, 13, 601.	5.8	40
395	Immunity to SARS-CoV-2 up to 15 months after infection. <i>IScience</i> , 2022, 25, 103743.	1.9	56
396	Comparing Coronavirus Disease 2019 (COVID-19) Pandemic Waves in Hospitalized Patients: A Retrospective, Multicenter, Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e389-e396.	2.9	7
397	Descriptive comparison of admission characteristics between pandemic waves and multivariable analysis of the association of the Alpha variant (B.1.1.7 lineage) of SARS-CoV-2 with disease severity in inner London. <i>BMJ Open</i> , 2022, 12, e055474.	0.8	12
398	COVID-19 and gut dysbiosis, understanding the role of probiotic supplements in reversing gut dysbiosis and immunity. <i>Nutrition Clinique Et Metabolisme</i> , 2022, 36, 153-161.	0.2	3
399	SARS-CoV-2 accessory protein ORF8 is secreted extracellularly as a glycoprotein homodimer. <i>Journal of Biological Chemistry</i> , 2022, 298, 101724.	1.6	28
400	Rapid detection of multiple SARS-CoV-2 variants of concern by PAM-targeting mutations. <i>Cell Reports Methods</i> , 2022, 2, 100173.	1.4	12
401	A review of the safety and efficacy of current COVID-19 vaccines. <i>Frontiers of Medicine</i> , 2022, 16, 39-55.	1.5	19
402	Aloin isoforms (A and B) selectively inhibits proteolytic and deubiquitinating activity of papain like protease (PLpro) of SARS-CoV-2 in vitro. <i>Scientific Reports</i> , 2022, 12, 2145.	1.6	22
403	A highly virulent variant of HIV-1 circulating in the Netherlands. <i>Science</i> , 2022, 375, 540-545.	6.0	39
404	Co-circulation of SARS-CoV-2 Alpha and Gamma variants in Italy, February and March 2021. <i>Eurosurveillance</i> , 2022, 27, .	3.9	20
405	CIMT 2021: report on the 18th Annual Meeting of the Association for Cancer Immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2022, , 1-10.	1.4	0
406	Epidemiological and clinical insights from SARS-CoV-2 RT-PCR crossing threshold values, France, January to November 2020. <i>Eurosurveillance</i> , 2022, 27, .	3.9	6
407	Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications. <i>Current Microbiology</i> , 2022, 79, 20.	1.0	48

#	ARTICLE	IF	CITATIONS
408	The emergence, genomic diversity and global spread of SARS-CoV-2. <i>Nature</i> , 2021, 600, 408-418.	13.7	249
409	CoV-Spectrum: analysis of globally shared SARS-CoV-2 data to identify and characterize new variants. <i>Bioinformatics</i> , 2022, 38, 1735-1737.	1.8	191
410	Infection With the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Delta Variant Is Associated With Higher Recovery of Infectious Virus Compared to the Alpha Variant in Both Unvaccinated and Vaccinated Individuals. <i>Clinical Infectious Diseases</i> , 2022, 75, e715-e725.	2.9	130
411	Biparatopic nanobodies protect mice from lethal challenge with SARS-CoV-2 variants of concern. <i>EMBO Reports</i> , 2022, 23, e53865.	2.0	18
412	Impact of COVID-19 Vaccination: A Global Perspective. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
413	Evolutionary history of the SARS-CoV-2 Gamma variant of concern (P.1): a perfect storm. <i>Genetics and Molecular Biology</i> , 2022, 45, e20210309.	0.6	8
414	Non-Markovian modelling highlights the importance of age structure on Covid-19 epidemiological dynamics. <i>Mathematical Modelling of Natural Phenomena</i> , 2022, 17, 7.	0.9	9
415	Inhibitor screening using microarray identifies the high capacity of neutralizing antibodies to Spike variants in SARS-CoV-2 infection and vaccination. <i>Theranostics</i> , 2022, 12, 2519-2534.	4.6	3
417	Vaccines alone will not prevent COVID-19 outbreaks among migrant workers—the example of meat processing plants. <i>Clinical Microbiology and Infection</i> , 2022, 28, 773-778.	2.8	13
419	COVID-19 Vaccine: Between Myth and Truth. <i>Vaccines</i> , 2022, 10, 349.	2.1	12
420	An overview of Brazilian working age adults vulnerability to COVID-19. <i>Scientific Reports</i> , 2022, 12, 2798.	1.6	5
421	Cultural-Religious Approach: An Effective Community-Based Disaster Management Strategy for Reducing the Mortality and Morbidity of the Fourth Wave of Coronavirus Pandemic Caused by the Lineage B.1.1.7 (the British Variant) in Iran (Spring 2021). <i>The Malaysian Journal of Medical Sciences</i> , 2022, 29, 154-156.	0.3	0
422	Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages. <i>Journal of Infectious Diseases</i> , 2022, 226, 808-811.	1.9	7
424	Assessment of Virological Contributions to COVID-19 Outcomes in a Longitudinal Cohort of Hospitalized Adults. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac027.	0.4	8
425	Assessment of Mutations Associated With Genomic Variants of SARS-CoV-2: RT-qPCR as a Rapid and Affordable Tool to Monitoring Known Circulating Variants in Chile, 2021. <i>Frontiers in Medicine</i> , 2022, 9, 841073.	1.2	2
426	Initial Proportion and Dynamic of B.1.1.7 SARS-CoV-2 in a Large City in the West of Germany. <i>Biomedicine Hub</i> , 2022, 7, 36-41.	0.4	0
427	Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2172.	1.8	5
428	Multiple COVID-19 Waves and Vaccination Effectiveness in the United States. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2282.	1.2	36

#	ARTICLE	IF	CITATIONS
429	Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants. <i>PLoS Pathogens</i> , 2022, 18, e1010260.	2.1	81
430	Emergency SARS-CoV-2 Variants of Concern: Novel Multiplex Real-Time RT-PCR Assay for Rapid Detection and Surveillance. <i>Microbiology Spectrum</i> , 2022, 10, e0251321.	1.2	35
431	Evolutionary dynamics of the severe acute respiratory syndrome coronavirus 2 genomes. <i>Medical Review</i> , 2022, 2, 3-22.	0.3	7
433	Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy. <i>Medical Microbiology and Immunology</i> , 2022, 211, 79-103.	2.6	9
434	Structural and Computational Studies of the SARS-CoV-2 Spike Protein Binding Mechanisms with Nanobodies: From Structure and Dynamics to Avidity-Driven Nanobody Engineering. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2928.	1.8	8
435	Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2 Mice Conferred by an Intranasal Nanobody (Nb22). <i>Frontiers in Immunology</i> , 2022, 13, 865401.	2.2	8
437	CovDif, a Tool to Visualize the Conservation between SARS-CoV-2 Genomes and Variants. <i>Viruses</i> , 2022, 14, 561.	1.5	1
438	Age-specific rate of severe and critical SARS-CoV-2 infections estimated with multi-country seroprevalence studies. <i>BMC Infectious Diseases</i> , 2022, 22, 311.	1.3	43
439	New laboratory evidence for the association between endothelial dysfunction and COVID-19 disease progression. <i>Journal of Medical Virology</i> , 2022, 94, 3112-3120.	2.5	12
441	Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617. <i>Nature Communications</i> , 2022, 13, 1638.	5.8	11
445	SARS-CoV-2 variants, immune escape, and countermeasures. <i>Frontiers of Medicine</i> , 2022, 16, 196-207.	1.5	39
447	Evolution of the SARS-CoV-2 spike protein in the human host. <i>Nature Communications</i> , 2022, 13, 1178.	5.8	44
449	Divergent trajectories of antiviral memory after SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, 1251.	5.8	20
450	Human Placenta-derived Amniotic epithelial cells as a new therapeutic hope for COVID-19-associated acute respiratory distress syndrome (ARDS) and systemic inflammation. <i>Stem Cell Research and Therapy</i> , 2022, 13, 126.	2.4	15
452	The influence of COVID-19 pandemic on biomedical waste management, the impact beyond infection. <i>Proceedings of the Indian National Science Academy</i> , 2022, 88, 117-128.	0.5	7
453	The Successes and Challenges of SARS-CoV-2 Molecular Testing in the United States. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 147-160.	0.7	6
454	Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 69.	7.1	19
455	Multimorbidity Profile of COVID-19 Deaths in Portugal during 2020. <i>Journal of Clinical Medicine</i> , 2022, 11, 1898.	1.0	4

#	ARTICLE	IF	CITATIONS
456	Case Report of a COVID-19 Sub-acute Patient with Rehabilitation Therapy. The Japanese Journal of Rehabilitation Medicine, 2022, , .	0.0	1
457	Comparative Analysis of B.1.617.2 (Delta) Variant of SARS-CoV-2. Journal of Microbiology and Infectious Diseases, 0, , 38-51.	0.1	0
458	SARS-CoV-2 variants and vulnerability at the global level. Journal of Medical Virology, 2022, 94, 2986-3005.	2.5	79
459	IFITM3, FURIN, ACE1, and TNF-Î± Genetic Association With COVID-19 Outcomes: Systematic Review and Meta-Analysis. Frontiers in Genetics, 2022, 13, 775246.	1.1	10
460	Eigenvalue analysis of SARS-CoV-2 viral load data: illustration for eight COVID-19 patients. International Journal of Data Science and Analytics, 2022, , 1-10.	2.4	2
461	Spike protein of SARS-CoV-2 variants: a brief review and practical implications. Brazilian Journal of Microbiology, 2022, 53, 1133-1157.	0.8	22
462	Impact of COVID-19 immunisation on COVID-19 incidence, hospitalisations, and deaths by age group in Germany from December 2020 to October 2021. Vaccine, 2022, 40, 2910-2914.	1.7	3
463	Epitope mapping of neutralising anti-SARS-CoV-2 monoclonal antibodies: Implications for immunotherapy and vaccine design. Reviews in Medical Virology, 2022, 32, e2347.	3.9	7
464	Multi-scale modelling reveals that early super-spreader events are a likely contributor to novel variant predominance. Journal of the Royal Society Interface, 2022, 19, 20210811.	1.5	16
465	The Alpha Variant (B.1.1.7) of SARS-CoV-2 Failed to Become Dominant in Mexico. Microbiology Spectrum, 2022, 10, e0224021.	1.2	21
466	Large-Scale SARS-CoV-2 Antigen Testing With Real-World Specimens. Frontiers in Public Health, 2022, 10, 836328.	1.3	9
467	Variant-specific SARS-CoV-2 within-host kinetics. Journal of Medical Virology, 2022, 94, 3625-3633.	2.5	11
468	The new normal: Covid-19 risk perceptions and support for continuing restrictions past vaccinations. PLoS ONE, 2022, 17, e0266602.	1.1	6
469	Evaluation of electropolymerized molecularly imprinted polymers (E-MIPs) on disposable electrodes for detection of SARS-CoV-2 in saliva. Analytica Chimica Acta, 2022, 1206, 339777.	2.6	42
470	Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines. EBioMedicine, 2022, 79, 103986.	2.7	23
471	The status and analysis of common mutations found in the SARS-CoV-2 whole genome sequences from Bangladesh. Gene Reports, 2022, 27, 101608.	0.4	2
472	SARS-CoV-2 B.1.214.1, B.1.214.2 and B.1.620 are predominant lineages between December 2020 and July 2021 in the Republic of Congo. IJID Regions, 2022, 3, 106-113.	0.5	1
473	The Influence of SARS-CoV-2 Variants on National Case-Fatality Rates: Correlation and Validation Study. Jmirx Med, 2022, 3, e32935.	0.2	9

#	ARTICLE	IF	CITATIONS
474	Reimagining quarantine: Assuring hopefulness in nursing and healthcare. <i>Nursing Inquiry</i> , 2021, , e12481.	1.1	0
478	Modeling the onset of symptoms of COVID-19: Effects of SARS-CoV-2 variant. <i>PLoS Computational Biology</i> , 2021, 17, e1009629.	1.5	17
479	Dynamics of SARS-CoV-2 Variants of Concern in Brazil, Early 2021. <i>Frontiers in Public Health</i> , 2021, 9, 784300.	1.3	6
480	Multicenter study evaluating one multiplex RT-PCR assay to detect SARS-CoV-2, influenza A/B, and respiratory syncytia virus using the LabTurbo AIO open platform: epidemiological features, automated sample-to-result, and high-throughput testing. <i>Aging</i> , 2021, 13, 24931-24942.	1.4	10
481	The Development of SARS-CoV-2 Variants: The Gene Makes the Disease. <i>Journal of Developmental Biology</i> , 2021, 9, 58.	0.9	27
482	Earlier In Vitro Viral Production With SARS-CoV-2 Alpha Than With Beta, Gamma, B, or A.27 Variants. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 792202.	1.8	1
483	Evolution of enhanced innate immune evasion by SARS-CoV-2. <i>Nature</i> , 2022, 602, 487-495.	13.7	237
484	Demographic and Clinical Overview of Hospitalized COVID-19 Patients during the First 17 Months of the Pandemic in Poland. <i>Journal of Clinical Medicine</i> , 2022, 11, 117.	1.0	18
485	Estimating the strength of selection for new SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 7239.	5.8	23
486	Geographical Landscape and Transmission Dynamics of SARS-CoV-2 Variants Across India: A Longitudinal Perspective. <i>Frontiers in Genetics</i> , 2021, 12, 753648.	1.1	7
488	SARS-CoV-2 Infection Causes Hyperglycemia in Cats. <i>Journal of Infectious Diseases</i> , 2022, 226, 1568-1576.	1.9	4
489	Which vaccination strategy against COVID-19?. <i>International Health</i> , 2023, 15, 150-160.	0.8	0
490	Honeysuckle (<i>Lonicera japonica</i>) and Huangqi (<i>Astragalus membranaceus</i>) Suppress SARS-CoV-2 Entry and COVID-19 Related Cytokine Storm in Vitro. <i>Frontiers in Pharmacology</i> , 2021, 12, 765553.	1.6	24
492	Computer Simulations and Network-Based Profiling of Binding and Allosteric Interactions of SARS-CoV-2 Spike Variant Complexes and the Host Receptor: Dissecting the Mechanistic Effects of the Delta and Omicron Mutations. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4376.	1.8	16
493	Psychological stress self-help interventions for healthcare workers in the context of COVID-19 in China: A randomized controlled trial protocol. <i>Internet Interventions</i> , 2022, 28, 100541.	1.4	3
494	Intrinsic Severity of the SARS-CoV-2 Omicron Variant. <i>New England Journal of Medicine</i> , 2022, 386, 1867-1868.	13.9	3
495	Evaluation of SARS-CoV-2 diagnostics and risk factors associated with SARS-CoV-2 infection in Zambia. <i>International Journal of Infectious Diseases</i> , 2022, 120, 150-157.	1.5	4
496	Safety and Immunogenicity of Inactivated COVID-19 Vaccines Among People Living with HIV in China. <i>Infection and Drug Resistance</i> , 2022, Volume 15, 2091-2100.	1.1	18

#	ARTICLE	IF	CITATIONS
497	Epidemiology of SARS-CoV-2 infection in nursing facilities and the impact of their clusters in a Japanese core city. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 955-961.	0.8	4
498	Health system impacts of SARS-CoV-2 variants of concern: a rapid review. <i>BMC Health Services Research</i> , 2022, 22, 544.	0.9	10
499	Clinical Characteristics, Transmissibility, Pathogenicity, Susceptible Populations, and Re-infectivity of Prominent COVID-19 Variants. , 2022, 13, 402.		28
500	SARS-CoV-2 Variants of Concern Increased Transmission and Decrease Vaccine Efficacy in the COVID-19 Pandemic in Palembang Indonesia.. <i>Acta Biomedica</i> , 2022, 93, e2022018.	0.2	0
501	The impact of shifting demographics, variants of concern and vaccination on outcomes during the first 3 COVID-19 waves in Alberta and Ontario: a retrospective cohort study. <i>CMAJ Open</i> , 2022, 10, E400-E408.	1.1	16
502	Two DNA vaccines protect against severe disease and pathology due to SARS-CoV-2 in Syrian hamsters. <i>Npj Vaccines</i> , 2022, 7, 49.	2.9	7
503	Neutralization heterogeneity of circulating SARS-CoV-2 variants to sera elicited by a vaccinee or convalescent. <i>Future Virology</i> , 2022, 17, 403-413.	0.9	6
504	RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge. <i>Translational Research</i> , 2022, 248, 11-21.	2.2	13
505	Phylogenetic Dispersal of SARS-CoV-2 Lineages Circulating across Polish-German Border Provinces. <i>Viruses</i> , 2022, 14, 884.	1.5	2
506	Author's Responses to Peer Reviews of "The Influence of SARS-CoV-2 Variants on National Case-Fatality Rates: Correlation and Validation Study". <i>Jmirx Med</i> , 2022, 3, e38549.	0.2	0
507	Identifying SARS-CoV-2 Variants of Concern through Saliva-Based RT-qPCR by Targeting Recurrent Mutation Sites. <i>Microbiology Spectrum</i> , 2022, 10, e0079722.	1.2	3
508	COVID-19 Vaccines and the Efficacy of Currently Available Vaccines Against COVID-19 Variants. <i>Cureus</i> , 2022, , .	0.2	3
509	Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine. <i>JAMA Network Open</i> , 2022, 5, e2210780.	2.8	27
510	Spatial and temporal fluctuations in COVID-19 fatality rates in Brazilian hospitals. <i>Nature Medicine</i> , 2022, 28, 1476-1485.	15.2	24
511	SARS-CoV-2 variants " Evolution, spike protein, and vaccines. <i>Biomedical Journal</i> , 2022, 45, 573-579.	1.4	26
512	SARS-CoV-2 Virion Infectivity and Cytokine Production in Primary Human Airway Epithelial Cells. <i>Viruses</i> , 2022, 14, 951.	1.5	6
513	First importations of SARS-CoV-2 P.1 and P.2 variants from Brazil to Spain and early community transmission. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2022, 40, 262-265.	0.2	0
514	Olfactory dysfunction is more severe in wild-type SARS-CoV-2 infection than in the Delta variant (B.1.617.2). <i>World Allergy Organization Journal</i> , 2022, 15, 100653.	1.6	12

#	ARTICLE	IF	CITATIONS
516	Epidemiological and genomic findings of the first documented Italian outbreak of SARS-CoV-2 Alpha variant of concern. <i>Epidemics</i> , 2022, 39, 100578.	1.5	4
518	The third international hackathon for applying insights into large-scale genomic composition to use cases in a wide range of organisms. <i>F1000Research</i> , 0, 11, 530.	0.8	1
519	Molecular evolution and structural analyses of the spike glycoprotein from Brazilian SARS-CoV-2 genomes: the impact of selected mutations. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 3110-3128.	2.0	1
520	Assessment of mortality and hospital admissions associated with confirmed infection with SARS-CoV-2 Alpha variant: a matched cohort and time-to-event analysis, England, October to December 2020. <i>Eurosurveillance</i> , 2022, 27, .	3.9	8
521	High prevalence of an alpha variant lineage with a premature stop codon in ORF7a in Iraq, winter 2020â€“2021. <i>PLoS ONE</i> , 2022, 17, e0267295.	1.1	8
522	Impact of non-pharmaceutical interventions and vaccination on COVID-19 outbreaks in Nunavut, Canada: a Canadian Immunization Research Network (CIRN) study. <i>BMC Public Health</i> , 2022, 22, .	1.2	4
526	Peer Review of â€œThe Influence of SARS-CoV-2 Variants on National Case-Fatality Rates: Correlation and Validation Studyâ€. <i>Jmirx Med</i> , 2022, 3, e38547.	0.2	1
527	COVID-19: VARIANTS, VACCINES, AND ADVERSE REACTIONS. <i>Innovare Journal of Medical Sciences</i> , 0, , 6-13.	0.2	0
528	The Study of Alternative Fire Commandersâ€™ Training Program during the COVID-19 Pandemic Situation in New Taipei City, Taiwan. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 6633.	1.2	0
529	COVID-19-Current Therapeutical Approaches and Future Perspectives. <i>Processes</i> , 2022, 10, 1053.	1.3	1
530	Competition for dominance within replicating quasispecies during prolonged SARS-CoV-2 infection in an immunocompromised host. <i>Virus Evolution</i> , 2022, 8, .	2.2	21
531	Anatomy of the first six months of COVID-19 vaccination campaign in Italy. <i>PLoS Computational Biology</i> , 2022, 18, e1010146.	1.5	5
532	An early warning system for emerging SARS-CoV-2 variants. <i>Nature Medicine</i> , 2022, 28, 1110-1115.	15.2	47
533	Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines. <i>Vaccine</i> , 2022, 40, 4017-4025.	1.7	7
534	SARSâ€“CoVâ€“2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in Mice. <i>Small</i> , 2022, 18, .	5.2	11
535	Severity of infection with the SARS-CoV-2 B.1.1.7 lineage among hospitalized COVID-19 patients in Belgium. <i>PLoS ONE</i> , 2022, 17, e0269138.	1.1	3
536	Modeling waning and boosting of COVID-19 in Canada with vaccination. <i>Epidemics</i> , 2022, 39, 100583.	1.5	29
537	Time Trend in SARS-CoV-2 Seropositivity, Surveillance Detection- and Infection Fatality Ratio until Spring 2021 in the Tirschenreuth Countyâ€™ Results from a Population-Based Longitudinal Study in Germany. <i>Viruses</i> , 2022, 14, 1168.	1.5	4

#	ARTICLE	IF	CITATIONS
538	Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. <i>Vaccines</i> , 2022, 10, 919.	2.1	23
539	Household Secondary Transmission of the Severe Acute Respiratory Syndrome Coronavirus 2 Alpha Variant From a Community Cluster in a Nursery in Japan. <i>Pediatric Infectious Disease Journal</i> , 0, Publish Ahead of Print, .	1.1	1
540	Increased risk of severe COVID-19 in hospitalized patients with SARS-CoV-2 Alpha variant infection: a multicentre matched cohort study. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	1
541	Singular Interface Dynamics of the SARS-CoV-2 Delta Variant Explained with Contact Perturbation Analysis. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 3107-3122.	2.5	5
542	Exploring the Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Asia Pacific Countries and Territories: A Discussion Paper. <i>International Journal of Translational Medicine</i> , 2022, 2, 275-308.	0.1	1
543	Age-Dependent Risks of COVID-19 Putatively Caused by Variant Alpha in Japan. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	4
544	Advancements in Testing Strategies for COVID-19. <i>Biosensors</i> , 2022, 12, 410.	2.3	8
545	Dual Inhibition of Vacuolar-ATPase and TMPRSS2 Is Required for Complete Blockade of SARS-CoV-2 Entry into Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	20
547	Smartphone-Based SARS-CoV-2 and Variants Detection System using Colorimetric DNAzyme Reaction Triggered by Loop-Mediated Isothermal Amplification (LAMP) with Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR). <i>ACS Nano</i> , 2022, 16, 11300-11314.	7.3	48
548	Adjusting for time of infection or positive test when estimating the risk of a post-infection outcome in an epidemic. <i>Statistical Methods in Medical Research</i> , 2022, 31, 1942-1958.	0.7	9
549	SARS-CoV-2: phenotype, genotype, and characterization of different variants. <i>Cellular and Molecular Biology Letters</i> , 2022, 27, .	2.7	12
551	Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6735.	1.8	7
552	Recapping the Features of SARS-CoV-2 and Its Main Variants: Status and Future Paths. <i>Journal of Personalized Medicine</i> , 2022, 12, 995.	1.1	9
553	Automated Library Construction and Analysis for High-throughput Nanopore Sequencing of SARS-CoV-2. <i>journal of applied laboratory medicine</i> , The, 0, , .	0.6	0
554	Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California. <i>Nature Medicine</i> , 2022, 28, 1933-1943.	15.2	243
555	Clinical Severity of SARS-CoV-2 Omicron Variant Compared with Delta among Hospitalized COVID-19 Patients in Belgium during Autumn and Winter Season 2021â€“2022. <i>Viruses</i> , 2022, 14, 1297.	1.5	41
556	Structural basis of Omicron immune evasion: A comparative computational study. <i>Computers in Biology and Medicine</i> , 2022, 147, 105758.	3.9	6
557	Frustration-driven allosteric regulation and signal transmission in the SARS-CoV-2 spike omicron trimer structures: a crosstalk of the omicron mutation sites allosterically regulates tradeoffs of protein stability and conformational adaptability. <i>Physical Chemistry Chemical Physics</i> , 0, , .	1.3	9

#	ARTICLE	IF	CITATIONS
560	Hybrid CRSIPR/Cas Protein for One-Pot Detection of DNA and RNA. SSRN Electronic Journal, 0, , .	0.4	1
561	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	59
562	Evaluation of Clinical Course of Gamma (P.1) Variant of Concern versus Lineages in Hospitalized Patients with COVID-19 in a Reference Center in Brazil. American Journal of Tropical Medicine and Hygiene, 2022, 107, 245-251.	0.6	3
563	Rapid, adaptable and sensitive Cas13-based COVID-19 diagnostics using ADESSO. Nature Communications, 2022, 13, .	5.8	36
564	A paper-based assay for the colorimetric detection of SARS-CoV-2 variants at single-nucleotide resolution. Nature Biomedical Engineering, 2022, 6, 957-967.	11.6	83
565	Genomic surveillance of SARS-CoV-2 in US military compounds in Afghanistan reveals multiple introductions and outbreaks of Alpha and Delta variants. BMC Genomics, 2022, 23, .	1.2	2
566	Altered subgenomic RNA abundance provides unique insight into SARS-CoV-2 B.1.1.7/Alpha variant infections. Communications Biology, 2022, 5, .	2.0	12
567	Assessing Public Health and Social Measures Against COVID-19 in Japan From March to June 2021. Frontiers in Medicine, 0, 9, .	1.2	6
568	Early detection and surveillance of SARS-CoV-2 genomic variants in wastewater using COJAC. Nature Microbiology, 2022, 7, 1151-1160.	5.9	69
569	Whole-genome analysis and mutation pattern of SARS-CoV-2 during first and second wave outbreak in Gwangju, Republic of Korea. Scientific Reports, 2022, 12, .	1.6	6
570	Clinical and survival differences during separate COVID-19 surges: Investigating the impact of the Sars-CoV-2 alpha variant in critical care patients. PLoS ONE, 2022, 17, e0269244.	1.1	3
572	SARS-CoV-2 Genomic Characteristics and Clinical Impact of SARS-CoV-2 Viral Diversity in Critically Ill COVID-19 Patients: A Prospective Multicenter Cohort Study. Viruses, 2022, 14, 1529.	1.5	4
573	A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses. Frontiers in Immunology, 0, 13, .	2.2	8
574	Clinical Performance Characteristics of the Swift Normalase Amplicon Panel for Sensitive Recovery of Severe Acute Respiratory Syndrome Coronavirus 2 Genomes. Journal of Molecular Diagnostics, 2022, 24, 963-976.	1.2	7
575	First COVID-19 Booster Dose in the General Population: A Systematic Review and Meta-Analysis of Willingness and Its Predictors. Vaccines, 2022, 10, 1097.	2.1	34
576	Maresin-1 and its receptors ROR1/LGR6 as potential therapeutic target for respiratory diseases. Pharmacological Research, 2022, 182, 106337.	3.1	9
577	Clinical Aspects of the Subsequent SARS-CoV-2 Waves in Children from 2020 to 2022—Data from a Local Cohort in Cologne, Germany (n = 21,635). Viruses, 2022, 14, 1607.	1.5	5
578	Study of protease-mediated processes initiating viral infection and cell-to-cell viral spreading of SARS-CoV-2. Journal of Molecular Modeling, 2022, 28, .	0.8	2

#	ARTICLE	IF	CITATIONS
579	A comparison of high-throughput SARS-CoV-2 sequencing methods from nasopharyngeal samples. <i>Scientific Reports</i> , 2022, 12, .	1.6	10
580	Molecular characterization of SARS-CoV-2 detected in Tokyo, Japan during five waves: Identification of the amino acid substitutions associated with transmissibility and severity. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	7
581	Interferon resistance of emerging SARS-CoV-2 variants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	63
582	Nanomechanical analysis of SARS-CoV-2 variants and predictions of infectiousness and lethality. <i>Soft Matter</i> , 2022, 18, 5833-5842.	1.2	3
583	COVID-19-Related Symptoms during the SARS-CoV-2 Omicron (B.1.1.529) Variant Surge in Japan. <i>Tohoku Journal of Experimental Medicine</i> , 2022, 258, 103-110.	0.5	10
584	COVID-19 Severity and Mortality in Two Pandemic Waves in Poland and Predictors of Poor Outcomes of SARS-CoV-2 Infection in Hospitalized Young Adults. <i>Viruses</i> , 2022, 14, 1700.	1.5	7
585	An analysis of 45 large-scale wastewater sites in England to estimate SARS-CoV-2 community prevalence. <i>Nature Communications</i> , 2022, 13, .	5.8	53
586	Inactivated COVID-19 vaccines: durability of Covaxin/BBV152 induced immunity against variants of concern. <i>Journal of Travel Medicine</i> , 2022, 29, .	1.4	10
587	The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in the UK. <i>Virus Evolution</i> , 2022, 8, .	2.2	75
588	An intranasal ASO therapeutic targeting SARS-CoV-2. <i>Nature Communications</i> , 2022, 13, .	5.8	29
589	Modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era. <i>Nature Communications</i> , 2022, 13, .	5.8	34
590	Evolutionary remodelling of Nâ€terminal domain loops fineâ€tunes <sc>SARSâ€CoV</sc>â€ spike. <i>EMBO Reports</i> , 2022, 23, .	2.0	18
591	Reduction in risk of death among patients admitted with COVID-19 between first and second epidemic waves in New York City. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	1
592	Two Years into the COVID-19 Pandemic: Lessons Learned. <i>ACS Infectious Diseases</i> , 2022, 8, 1758-1814.	1.8	47
593	Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study. <i>BMJ</i> , The, 0, , e070695.	3.0	98
594	How to differentiate the B.1.1.7 variant from COVID-19 in hospitalized patients?. <i>The European Research Journal</i> , 0, , 1-7.	0.1	0
595	Folic acid and methotrexate use and their association with COVID-19 diagnosis and mortality: a caseâ€control analysis from the UK Biobank. <i>BMJ Open</i> , 2022, 12, e062945.	0.8	7
596	Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination. <i>International Immunopharmacology</i> , 2022, 111, 109128.	1.7	9

#	ARTICLE	IF	CITATIONS
597	Regional importation and asymmetric within-country spread of SARS-CoV-2 variants of concern in the Netherlands. <i>ELife</i> , 0, 11, .	2.8	12
598	Laboratory markers of severity across three COVID-19 outbreaks in Australia: has Omicron and vaccinations changed disease presentation?. <i>Internal and Emergency Medicine</i> , 2023, 18, 43-52.	1.0	8
599	State-of-art high-performance Nano-systems for mutated coronavirus infection management: From Lab to Clinic. <i>OpenNano</i> , 2022, 8, 100078.	1.8	11
600	SARS-CoV-2 Vaccine Against Virus: Mission Accomplished!?. , 2022, , 561-574.		0
601	Assessing the Impact of SARS-CoV-2 Lineages and Mutations on Patient Survival. <i>Viruses</i> , 2022, 14, 1893.	1.5	3
602	SARS-CoV-2 Delta variant induces enhanced pathology and inflammatory responses in K18-hACE2 mice. <i>PLoS ONE</i> , 2022, 17, e0273430.	1.1	17
603	Clinical characteristics analysis of COVID-19 patients from the first significant community outbreak by SARS-CoV-2 variant B.1.1.7 in Taiwan as experienced from a single northern medical center. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, 55, 1036-1043.	1.5	7
604	Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, .	5.8	8
605	Advanced Molecular Tweezers with Lipid Anchors against SARS-CoV-2 and Other Respiratory Viruses. <i>Jacs Au</i> , 2022, 2, 2187-2202.	3.6	4
606	The Spike-Stabilizing D614G Mutation Interacts with S1/S2 Cleavage Site Mutations To Promote the Infectious Potential of SARS-CoV-2 Variants. <i>Journal of Virology</i> , 2022, 96, .	1.5	6
607	Whole-genome sequencing of SARS-CoV-2: Comparison of target capture and amplicon single molecule real-time sequencing protocols. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	5
608	A novel cyclic β -AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein. <i>Cell Discovery</i> , 2022, 8, .	3.1	13
609	Predicting onset risk of COVID-19 symptom to support healthy travel route planning in the new normal of long-term coexistence with SARS-CoV-2. <i>Environment and Planning B: Urban Analytics and City Science</i> , 0, , 239980832211277.	1.0	0
610	Epitope mapping of severe acute respiratory syndrome coronavirus 2 neutralizing receptor binding domain-specific monoclonal antibodies. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
611	Accessible and Adaptable Multiplexed Real-Time PCR Approaches to Identify SARS-CoV-2 Variants of Concern. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	9
612	Pathogen evolution during vaccination campaigns. <i>PLoS Biology</i> , 2022, 20, e3001804.	2.6	11
613	Assessing the impact of the four COVID-19 variants and the vaccine coverage on mortality in Malta over 2 years: An observational case study. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	1
614	Evolving trend change during the COVID-19 pandemic. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	8

#	ARTICLE	IF	CITATIONS
615	Delta variant: Partially sensitive to vaccination, but still worth global attention. <i>Journal of Translational Internal Medicine</i> , 2022, 10, 227-235.	1.0	2
616	Localized delivery of nanomedicine and antibodies for combating COVID-19. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1828-1846.	5.7	5
617	Real-world effectiveness of steroids in severe COVID-19: a retrospective cohort study. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	1
618	A cross-sectional national investigation of COVID-19 outbreaks in nurseries during rapid spread of the Alpha (B.1.1.7) variant of SARS-CoV-2 in England. <i>BMC Public Health</i> , 2022, 22, .	1.2	1
619	Comparison of Clinical Characteristics and Outcomes of Hospitalized Patients Infected with the D614G Strain or Alpha Variant of COVID-19 in Taiwan: A Multi-Center Cohort Study. <i>International Journal of Medical Sciences</i> , 2022, 19, 1912-1919.	1.1	1
620	Importancia de la vigilancia genómica de SARS-CoV-2 en los tiempos de las vacunas contra la COVID-19. <i>Revista De La Universidad Industrial De Santander Salud</i> , 2022, 54, .	0.0	0
621	Perspective Chapter: Real-Time Genomic Surveillance for SARS-CoV-2 on Center Stage. <i>Infectious Diseases</i> , 0, , .	4.0	0
622	Validation of a new strategy for the identification of SARS-CoV-2 variants by sequencing the spike gene by Sanger. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2023, 41, 284-289.	0.2	1
623	Probabilistic Approach to COVID-19 Data Analysis and Forecasting Future Outbreaks Using a Multi-Layer Perceptron Neural Network. <i>Diagnostics</i> , 2022, 12, 2539.	1.3	9
624	A Timeframe for SARS-CoV-2 Genomes: A Proof of Concept for Postmortem Interval Estimations. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12899.	1.8	1
625	COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	77
627	SARS-CoV-2 variants of concern: a review. <i>Monaldi Archives for Chest Disease</i> , 0, , .	0.3	4
628	Risk of severe COVID-19 infection in persons with diabetes during the first and second waves in Denmark: A nationwide cohort study. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	4
629	Prerequisite for COVID-19 Prediction: A Review on Factors Affecting the Infection Rate. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 12997.	1.2	3
630	Infection with SARS-CoV-2 Variants Is Associated with Different Long COVID Phenotypes. <i>Viruses</i> , 2022, 14, 2367.	1.5	21
631	COVID-19 Vaccination is not a Sufficient Public Policy to face Crisis Management of next Pandemic Threats. <i>Public Organization Review</i> , 2023, 23, 1353-1367.	1.1	16
632	A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR). <i>European Respiratory Journal</i> , 2023, 61, 2101870.	3.1	22
633	Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation. <i>Chemico-Biological Interactions</i> , 2022, 368, 110244.	1.7	4

#	ARTICLE	IF	CITATIONS
634	A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19. <i>Life</i> , 2022, 12, 1758.	1.1	9
635	Hybrid CRISPR/Cas protein for one-pot detection of DNA and RNA. <i>Biosensors and Bioelectronics</i> , 2023, 219, 114819.	5.3	12
636	Homologous and heterologous booster vaccinations of S-268019-b, a recombinant S protein-based vaccine with a squalene-based adjuvant, enhance neutralization breadth against SARS-CoV-2 Omicron subvariants in cynomolgus macaques. <i>Vaccine</i> , 2022, 40, 7520-7525.	1.7	4
637	SARS-CoV-2 variant Alpha has a spike-dependent replication advantage over the ancestral B.1 strain in human cells with low ACE2 expression. <i>PLoS Biology</i> , 2022, 20, e3001871.	2.6	11
638	Ascertainment rate of SARS-CoV-2 infections from healthcare and community testing in the UK. <i>Journal of Theoretical Biology</i> , 2023, 558, 111333.	0.8	12
639	Lung fibrosis: Post-COVID-19 complications and evidences. <i>International Immunopharmacology</i> , 2023, 116, 109418.	1.7	14
640	A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	5
641	The importance of sustained compliance with physical distancing during COVID-19 vaccination rollout. <i>Communications Medicine</i> , 2022, 2, .	1.9	5
642	The application of a novel 5-in-1 multiplex reverse transcriptase-PCR polymerase chain reaction assay for rapid detection of SARS-CoV-2 and differentiation between variants of concern. <i>International Journal of Infectious Diseases</i> , 2023, 127, 56-62.	1.5	1
643	SARS-CoV-2 intra-host single-nucleotide variants associated with disease severity. <i>Virus Evolution</i> , 2022, 8, .	2.2	4
644	Progress on COVID-19 Chemotherapeutics Discovery and Novel Technology. <i>Molecules</i> , 2022, 27, 8257.	1.7	4
645	Endemicity Is Not a Victory: The Unmitigated Downside Risks of Widespread SARS-CoV-2 Transmission. <i>Covid</i> , 2022, 2, 1689-1709.	0.7	3
646	Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	5
647	As the SARS-CoV-2 virus evolves, should Omicron subvariant BA.2 be subjected to quarantine, or should we learn to live with it?. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	5
648	Challenges and developments in universal vaccine design against SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2022, 7, .	2.9	25
649	Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial. <i>Annals of Internal Medicine</i> , 2022, 175, 1716-1727.	2.0	2
650	Interpretable and Predictive Deep Neural Network Modeling of the SARS-CoV-2 Spike Protein Sequence to Predict COVID-19 Disease Severity. <i>Biology</i> , 2022, 11, 1786.	1.3	4
651	Inferring selection effects in SARS-CoV-2 with Bayesian Viral Allele Selection. <i>PLoS Genetics</i> , 2022, 18, e1010540.	1.5	8

#	ARTICLE	IF	CITATIONS
654	SARS-CoV-2 variants: Evolution observed in a local hospital between 2020 and 2021. Tenri Medical Bulletin, 2022, 25, 126-132.	0.1	0
656	Molecular evolution of SARS-CoV-2 from December 2019 to August 2022. Journal of Medical Virology, 2023, 95, .	2.5	22
657	Ligation-based assay for variant typing without sequencing: Application to SARS-CoV-2 variants of concern. Influenza and Other Respiratory Viruses, 2023, 17, .	1.5	0
658	Genomic Epidemiology of SARS-CoV-2 in Western Burkina Faso, West Africa. Viruses, 2022, 14, 2788.	1.5	1
659	Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. Journal of Taibah University Medical Sciences, 2023, 18, 600-638.	0.5	1
660	Clinical outcomes of COVID-19 caused by the Alpha variant compared with one by wild type in Kobe, Japan. A multi-center nested case-control study. Journal of Infection and Chemotherapy, 2022, , .	0.8	0
661	Genomic epidemiology of SARS-CoV-2 in Cambodia, January 2020 to February 2021. Virus Evolution, 2023, 9, .	2.2	2
662	Severity of COVID-19 among Hospitalized Patients: Omicron Remains a Severe Threat for Immunocompromised Hosts. Viruses, 2022, 14, 2736.	1.5	10
663	Comparison of clinical characteristics of second and third peaks of COVID-19 pandemic: effects of vaccination and preventive measures. Minerva Respiratory Medicine, 2022, 61, .	0.1	0
664	SARS-CoV-2'İN SÄœREGELEN EVRÄ°MÄ°: PANDEMÄ°NÄ°N SONUNA NE KADAR YAKINIZ?. Journal of Biotechnology and Strategic Health Research, 0, , .	0.8	0
665	The mechanism shaping the logistic growth of mutation proportion in epidemics at population scale. Infectious Disease Modelling, 2023, 8, 107-121.	1.2	1
666	Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors. Viruses, 2023, 15, 175.	1.5	33
667	Risk of Covid-19 Severe Outcomes and Mortality in Migrants and Ethnic Minorities Compared to the General Population in the European WHO Region: a Systematic Review. Journal of International Migration and Integration, 2023, 24, 1305-1335.	0.8	9
668	Comparative outcomes of extracorporeal membrane oxygenation for COVID-19 delivered in experienced European centres during successive SARS-CoV-2 variant outbreaks (ECMO-SURGES): an international, multicentre, retrospective cohort study. Lancet Respiratory Medicine,the, 2023, 11, 163-175.	5.2	18
669	Sex differences and disparities in cardiovascular outcomes of COVID-19. Cardiovascular Research, 2023, 119, 1190-1201.	1.8	4
670	Cross-immunity against SARS-COV-2 variants of concern in naturally infected critically ill COVID-19 patients. Heliyon, 2023, 9, e12704.	1.4	2
671	COVID-19: A state of art on immunological responses, mutations, and treatment modalities in riposte. Journal of Infection and Public Health, 2023, 16, 233-249.	1.9	7
672	Efficacy and safety of metabolic interventions for the treatment of severe COVID-19: in vitro, observational, and non-randomized open-label interventional study. ELife, 0, 12, .	2.8	5

#	ARTICLE	IF	CITATIONS
673	Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines. Trends in Molecular Medicine, 2023, 29, 255-267.	3.5	17
674	Monitoring algorithm of hospitalized patients in a medical center with SARS-CoV-2 (Omicron variant) infection: clinical epidemiological surveillance and immunological assessment. PeerJ, 0, 11, e14666.	0.9	0
675	CRISPR-Cas13d effectively targets SARS-CoV-2 variants, including Delta and Omicron, and inhibits viral infection. MedComm, 2023, 4, .	3.1	3
676	Characteristics of patients with SARS-COV-2 PCR re-positivity after recovering from COVID-19. Epidemiology and Infection, 2023, 151, .	1.0	1
677	Current state-of-the-art review of nanotechnology-based therapeutics for viral pandemics: Special attention to COVID-19. Nanotechnology Reviews, 2023, 12, .	2.6	1
678	SARS-CoV-2 infection and immune responses. AIMS Microbiology, 2023, 9, 245-276.	1.0	2
679	Combining viral genomics and clinical data to assess risk factors for severe COVID-19 (mortality, ICU) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 2023, 18, e0283447.	1.1	0
680	Future foods: Morphological scenarios to explore changes in the UK food system with implications for food safety across the food chain. Futures, 2023, 149, 103140.	1.4	2
681	Accelerated cognitive decline after the COVID-19 pandemic in a community population of older persons with cognitive impairment: A 4-year time series analysis in the Tokyo Metropolis area. Geriatrics and Gerontology International, 2023, 23, 200-204.	0.7	3
682	Performance Evaluation of Different RT-PCR Kits for the Direct Detection of SARS-CoV-2 in Preheated Specimens. Journal of Laboratory Physicians, 0, , .	0.4	1
684	Variant-specific deleterious mutations in the SARS-CoV-2 genome reveal immune responses and potentials for prophylactic vaccine development. Frontiers in Pharmacology, 0, 14, .	1.6	15
685	A case of reinfection with a different variant of SARS-CoV-2: case report. The Egyptian Journal of Internal Medicine, 2023, 35, .	0.3	1
686	Whole-genome single molecule real-time sequencing of SARS-CoV-2 Omicron. Journal of Medical Virology, 2023, 95, .	2.5	3
687	Performance characteristics of the boson rapid SARS-cov-2 antigen test card vs RT-PCR: Cross-reactivity and emerging variants. Heliyon, 2023, 9, e13642.	1.4	0
688	Factors Influencing the Length of Hospital Stay Among Pediatric COVID-19 Patients at Queen Rania Al Abdullah Hospital for Children: A Cross-Sectional Study. Cureus, 2023, , .	0.2	0
689	An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. Heliyon, 2023, 9, e13952.	1.4	28
690	Assessment on serum CRP and serum ferritin level in COVID-19 patients of Dehradun Uttarakhand, India. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2023, 12, 623-628.	0.0	0
691	CRISPR techniques and potential for the detection and discrimination of SARS-CoV-2 variants of concern. TrAC - Trends in Analytical Chemistry, 2023, 161, 117000.	5.8	11

#	ARTICLE	IF	CITATIONS
692	Effectiveness of mRNA and viral vector vaccines in epidemic period led by different SARS-CoV-2 variants: A systematic review and meta-analysis. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
693	Total and Subgenomic RNA Viral Load in Patients Infected With SARS-CoV-2 Alpha, Delta, and Omicron Variants. <i>Journal of Infectious Diseases</i> , 2023, 228, 235-244.	1.9	1
694	Erythrocytes Functionality in SARS-CoV-2 Infection: Potential Link with Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5739.	1.8	2
695	Identification of berberine as a potential therapeutic strategy for kidney clear cell carcinoma and COVID-19 based on analysis of large-scale datasets. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
696	SARS-CoV-2 variant identification using a genome tiling array and genotyping probes. <i>Personalized Medicine</i> , 2023, 20, 13-25.	0.8	3
698	Travel history among persons infected with SARS-CoV-2 variants of concern in the United States, December 2020–February 2021. <i>PLOS Global Public Health</i> , 2023, 3, e0001252.	0.5	0
699	Tracking the Genomic Evolution of SARS-CoV-2 for 29 Months in South Korea. <i>Viruses</i> , 2023, 15, 873.	1.5	3
700	Do pathogens always evolve to be less virulent? The virulence–transmission trade-off in light of the COVID-19 pandemic. <i>Biologia Futura</i> , 0, , .	0.6	2
701	Factor Xa cleaves SARS-CoV-2 spike protein to block viral entry and infection. <i>Nature Communications</i> , 2023, 14, .	5.8	1
702	SARS-CoV-2: Structure, Pathogenesis, and Diagnosis. , 2024, , 24-51.		0
703	Phytochemicals of <i>Withania somnifera</i> as a Future Promising Drug against SARS-CoV-2: Pharmacological Role, Molecular Mechanism, Molecular Docking Evaluation, and Efficient Delivery. <i>Microorganisms</i> , 2023, 11, 1000.	1.6	2
704	The SARS-CoV-2 Alpha variant was associated with increased clinical severity of COVID-19 in Scotland: A genomics-based retrospective cohort analysis. <i>PLoS ONE</i> , 2023, 18, e0284187.	1.1	1
705	Immune interference in effectiveness of influenza and COVID-19 vaccination. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	7
716	Evolutionary implications of SARS-CoV-2 vaccination for the future design of vaccination strategies. <i>Communications Medicine</i> , 2023, 3, .	1.9	7
732	Community Protection. , 2023, , 1603-1624.e8.		0
738	Interaction of SARS-CoV-2 with host cells and antibodies: experiment and simulation. <i>Chemical Society Reviews</i> , 2023, 52, 6497-6553.	18.7	1
740	COVID-19 lag time and case fatality rate calculation tool, as well as a tool to identify when policymakers made mistakes. <i>Network Modeling Analysis in Health Informatics and Bioinformatics</i> , 2023, 12, .	1.2	0
757	Molecular biology of SARS-CoV-2 and techniques of diagnosis and surveillance. <i>Advances in Clinical Chemistry</i> , 2023, , .	1.8	0

#	ARTICLE	IF	CITATIONS
761	Overview of diagnostic tools and nano-based therapy of SARS-CoV-2 infection. Chemical Papers, 2024, 78, 2123-2154.	1.0	0
771	Applications of Mass Spectrometry in the Characterization, Screening, Diagnosis, and Prognosis of COVID-19. Advances in Experimental Medicine and Biology, 2024, , 33-61.	0.8	0